From bitopic inhibitors to multitarget drugs for the future treatment of Alzheimer's disease

Current Medicinal Chemistry

Volumn 22, Issue 33, 2015, Pages 3789-3806

  Pérez, Daniel I ^a   Martínez, Ana ^a   Gil, Carmen ^a   Campillo, Nuria E ^a  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

AChE; Alzheimer's disease; BACE 1; Bitopic drugs; BuChE; Cannabinoids; GSK3 ; Multitarget

Indexed keywords

BETA SECRETASE 1; BETA SECRETASE INHIBITOR; BITOPIC INHIBITOR; CANNABINOID 2 RECEPTOR; CHELATING AGENT; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DIMEBON; GLYCOGEN SYNTHASE KINASE 3BETA; HISTAMINE H3 RECEPTOR ANTAGONIST; LADOSTIGIL; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NOOTROPIC AGENT; UNCLASSIFIED DRUG; ACETYLCHOLINESTERASE;

ALZHEIMER DISEASE; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DRUG BINDING SITE; DRUG DESIGN; DRUG EFFICACY; DRUG TARGETING; HUMAN; IC50; MIXED DEMENTIA; MORRIS WATER MAZE TEST; MULTIINFARCT DEMENTIA; NEUROPROTECTION; NONHUMAN; PHARMACOPHORE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN AGGREGATION; REVIEW; STATIC ELECTRICITY; UPREGULATION; ANIMAL; CHEMISTRY; METABOLISM;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; ANIMALS; CHOLINESTERASE INHIBITORS; HUMANS;

EID: 84959499546     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867322666150812145825     Document Type: Review

References (134)

1. Duthey, B. Background Paper 6.11 Alzheimer Disease and other Dementias. Update on 2004 Background Paper 2013.
2. 2014 Alzheimer's Disease. Facts and Figures. Alzheimer's Association.
3. De-Paula, V.J.; Radanovic, M.; Diniz, B.S.; Forlenza, O.V. Alzheimer's disease. Subcell Biochem., 2012, 65, 329-352.
4. Imtiaz, B.; Tolppanen, A.M.; Kivipelto, M.; Soininen, H. Future directions in Alzheimer's disease from risk factors to prevention. Biochem. Pharmacol., 2014, 88, 661-670.
5. Fang, J.; Li, Y.; Liu, R.; Pang, X.; Li, C.; Yang, R.; He, Y.; Lian, W.; Liu, A.L.; Du, G.H. Discovery of multitargetdirected ligands against Alzheimer's disease through systematic prediction of chemical-protein interactions. J. Chem. Inf. Model, 2014, 149-164.
6. Agis-Torres, A.; Solhuber, M.; Fernandez, M.; Sanchez- Montero, J.M. Multi-target-directed ligands and other therapeutic strategies in the search of a real solution for Alzheimer's disease. Curr. Neuropharmacol., 2014, 12, 2-36.
7. Yiannopoulou, K.G.; Papageorgiou, S.G. Current and future treatments for Alzheimer's disease. Ther. Adv. Neurol. Disord., 2013, 6, 19-33.
8. Corbett, A.; Smith, J.; Ballard, C. New and emerging treatments for Alzheimer's disease. Expert. Rev. Neurother., 2012, 12, 535-543.
9. Schaeffer, E.L.; Gattaz, W.F. Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme. Psychopharmacology (Berl), 2008, 198, 1-27.
10. Butterfield, D.A.; Pocernich, C.B. The glutamatergic system and Alzheimer's disease: therapeutic implications. CNS Drugs, 2003, 17, 641-652.
11. Revett, T.J.; Baker, G.B.; Jhamandas, J.; Kar, S. Glutamate system, amyloid â peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology. J. Psychiatr. Neurosci., 2013, 38, 6-23.
12. Medina-Franco, J.L.; Giulianotti, M.A.; Welmaker, G.S.; Houghten, R.A. Shifting from the single to the multitarget paradigm in drug discovery. Drug Discov. Today, 2013, 18, 495-501.
13. Davie, B.J.; Christopoulos, A.; Scammells, P.J. Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits. ACS Chem. Neurosci., 2013, 4, 1026-1048.
14. Nickols, H.H.; Conn, P.J. Development of allosteric modulators of GPCRs for treatment of CNS disorders. Neurobiol. Dis., 2014, 61, 55-71.
15. Lane, J.R.; Sexton, P.M.; Christopoulos, A. Bridging the gap: bitopic ligands of G-protein-coupled receptors. Trends Pharmacol. Sci., 2013, 34, 59-66.
16. Mohr, K.; Schmitz, J.; Schrage, R.; Trankle, C.; Holzgrabe, U. Molecular alliance-from orthosteric and allosteric ligands to dualsteric/bitopic agonists at G protein coupled receptors. Angew. Chem. Int. Ed. Engl., 2013, 52, 508-516.
17. Bajda, M.; Guzior, N.; Ignasik, M.; Malawska, B. Multitarget- directed ligands in Alzheimer's disease treatment. Curr. Med. Chem., 2011, 18, 4949-4975.
18. Guzior, N.; Wieckowska, A.; Panek, D.; Malawska, B. Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease. Curr. Med. Chem., 2015, 22, 373-404.
19. Bottegoni, G.; Favia, A.D.; Recanatini, M.; Cavalli, A. The role of fragment-based and computational methods in polypharmacology. Drug Discov. Today, 2012, 17, 23-34.
20. Costantino, L.; Barlocco, D. Designed multiple ligands: basic research vs clinical outcomes. Curr. Med. Chem., 2012, 19, 3353-3387.
21. Cavalli, A.; Bolognesi, M.L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-targetdirected ligands to combat neurodegenerative diseases. J. Med. Chem., 2008, 51, 347-372.
22. Bolognesi, M.L.; Simoni, E.; Rosini, M.; Minarini, A.; Tumiatti, V.; Melchiorre, C. Multitarget-directed ligands: innovative chemical probes and therapeutic tools against Alzheimer's disease. Curr. Top. Med. Chem., 2011, 11, 2797-2806.
23. Olivera, S.; Rodriguez-Ithurralde, D.; Henley, J.M. Acetylcholinesterase promotes neurite elongation, synapse formation, and surface expression of AMPA receptors in hippocampal neurones. Mol. Cell Neurosci., 2003, 23, 96-106.
24. Chacon, M.A.; Reyes, A.E.; Inestrosa, N.C. Acetylcholinesterase induces neuronal cell loss, astrocyte hypertrophy and behavioral deficits in mammalian hippocampus. J. Neurochem., 2003, 87, 195-204.
25. Alvarez, A.; Bronfman, F.; Perez, C.A.; Vicente, M.; Garrido, J.; Inestrosa, N.C. Acetylcholinesterase, a senile plaque component, affects the fibrillogenesis of amyloidbeta- peptides. Neurosci. Lett., 1995, 201, 49-52.
26. Rees, T.; Hammond, P.I.; Soreq, H.; Younkin, S.; Brimijoin, S. Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex. Neurobiol. Aging, 2003, 24, 777-787.
27. De Ferrari, G.V.; Canales, M.A.; Shin, I.; Weiner, L.M.; Silman, I.; Inestrosa, N.C. A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation. Biochemistry, 2001, 40, 10447-10457.
28. Johnson, G.; Moore, S.W. The adhesion function on acetylcholinesterase is located at the peripheral anionic site. Biochem. Biophys. Res. Commun., 1999, 258, 758-762.
29. Castro, A.; Martinez, A. Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease. Mini Rev. Med. Chem., 2001, 1, 267-272.
30. Johnson, G.; Moore, S.W. The peripheral anionic site of acetylcholinesterase: structure, functions and potential role in rational drug design. Curr. Pharm. Des., 2006, 12, 217-225.
31. Garcia-Palomero, E.; Munoz, P.; Usan, P.; Garcia, P.; Delgado, E.; De Austria, C.; Valenzuela, R.; Rubio, L.; Medina, M.; Martinez, A. Potent beta-amyloid modulators. Neurodegener. Dis., 2008, 5, 153-156.
32. Castro, A.; Martinez, A. Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors. Curr. Pharm. Des., 2006, 12, 4377-4387.
33. Munoz-Torrero, D. Acetylcholinesterase inhibitors as disease- modifying therapies for Alzheimer's disease. Curr. Med. Chem., 2008, 15, 2433-2455.
34. Munoz-Torrero, D.; Camps, P. Huprines for Alzheimer's disease drug development. Expert. Opin. Drug Discov., 2008, 3, 65-81.
35. Rodrigues Simoes, M.C.; Dias Viegas, F.P.; Moreira, M.S.; de Freitas Silva, M.; Riquiel, M.M.; da Rosa, P.M.; Castelli, M.R.; dos Santos, M.H.; Soares, M.G.; Viegas, C., Jr. Donepezil: an important prototype to the design of new drug candidates for Alzheimer's disease. Mini Rev. Med. Chem., 2013, 14, 2-19.
36. del Monte-Millan, M.; Garcia-Palomero, E.; Valenzuela, R.; Usan, P.; de Austria, C.; Munoz-Ruiz, P.; Rubio, L.; Dorronsoro, I.; Martinez, A.; Medina, M. Dual binding site acetylcholinesterase inhibitors: potential new diseasemodifying agents for AD. J. Mol. Neurosci., 2006, 30, 85-88.
37. Melchiorre, C.; Bolognesi, M.L.; Minarini, A.; Rosini, M.; Tumiatti, V. Polyamines in drug discovery: from the universal template approach to the multitarget-directed ligand design strategy. J. Med. Chem., 2010, 53, 5906-5914.
38. Piazzi, L.; Rampa, A.; Bisi, A.; Gobbi, S.; Belluti, F.; Cavalli, A.; Bartolini, M.; Andrisano, V.; Valenti, P.; Recanatini, M. 3-(4-[[Benzyl(methyl)amino]methyl]phenyl)-6,7- dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced betaamyloid aggregation: a dual function lead for Alzheimer's disease therapy. J. Med. Chem., 2003, 46, 2279-2282.
39. Munoz-Ruiz, P.; Rubio, L.; Garcia-Palomero, E.; Dorronsoro, I.; del Monte-Millan, M.; Valenzuela, R.; Usan, P.; de Austria, C.; Bartolini, M.; Andrisano, V.; Bidon-Chanal, A.; Orozco, M.; Luque, F.J.; Medina, M.; Martinez, A. Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease. J. Med. Chem., 2005, 48, 7223-7233.
40. Rosenberry, T.L.; Sonoda, L.K.; Dekat, S.E.; Cusack, B.; Johnson, J.L. Monitoring the reaction of carbachol with acetylcholinesterase by thioflavin T fluorescence and acetylthiocholine hydrolysis. Chem. Biol. Interact., 2008, 175, 235-241.
41. Galdeano, C.; Viayna, E.; Arroyo, P.; Bidon-Chanal, A.; Blas, J.R.; Munoz-Torrero, D.; Luque, F.J. Structural determinants of the multifunctional profile of dual binding site acetylcholinesterase inhibitors as anti-Alzheimer agents. Curr. Pharm. Des., 2010, 16, 2818-2836.
42. Hou, L.N.; Xu, J.R.; Zhao, Q.N.; Gao, X.L.; Cui, Y.Y.; Xu, J.; Wang, H.; Chen, H.Z. A new motif in the N-terminal of acetylcholinesterase triggers amyloid-beta aggregation and deposition. CNS Neurosci. Ther., 2014, 20, 59-66.
43. Matera, C.; Tata, A.M. Pharmacological approaches to targeting muscarinic acetylcholine receptors. Recent Pat. CNS Drug Discov., 2014, 9, 85-100.
44. Keov, P.; Lopez, L.; Devine, S.M.; Valant, C.; Lane, J.R.; Scammells, P.J.; Sexton, P.M.; Christopoulos, A. Molecular mechanisms of bitopic ligand engagement with the M1 muscarinic acetylcholine receptor. J. Biol. Chem., 2014, 289, 23817-23837.
45. Zimmermann, G.R.; Lehar, J.; Keith, C.T. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov. Today, 2007, 12, 34-42.
46. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem., 2005, 48, 6523-6543.
47. Geldenhuys, W.J.; Youdim, M.B.; Carroll, R.T.; Van der Schyf, C.J. The emergence of designed multiple ligands for neurodegenerative disorders. Prog. Neurobiol., 2011, 94, 347-359.
48. Youdim, M.B. Why do we need multifunctional neuroprotective and neurorestorative drugs for Parkinson's and Alzheimer's diseases as disease modifying agents. Exp. Neurobiol., 2010, 19, 1-14.
49. Speck-Planche, A.; Luan, F.; Cordeiro, M.N. Role of ligand-based drug design methodologies toward the discovery of new anti- Alzheimer agents: futures perspectives in Fragment-Based Ligand Design. Curr. Med. Chem., 2012, 19, 1635-1645.
50. Zheng, H.; Fridkin, M.; Youdim, M. From single target to multitarget/network therapeutics in Alzheimer's therapy. Pharmaceuticals (Basel), 2014, 7, 113-135.
51. Morphy, R.; Rankovic, Z. Designing multiple ligands - medicinal chemistry strategies and challenges. Curr. Pharm. Des., 2009, 15, 587-600.
52. Tariot, P.N.; Farlow, M.R.; Grossberg, G.T.; Graham, S.M.; McDonald, S.; Gergel, I.; Memantine Study, G. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA, 2004, 291, 317-324.
53. Gauthier, S.; Molinuevo, J.L. Benefits of combined cholinesterase inhibitor and memantine treatment in moderatesevere Alzheimer's disease. Alzheimers Dement., 2013, 9, 326-331.
54. Porsteinsson, A.P.; Grossberg, G.T.; Mintzer, J.; Olin, J.T. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr. Alzheimer Res., 2008, 5, 83-89.
55. Grossberg, G.T.; Manes, F.; Allegri, R.F.; Gutierrez-Robledo, L.M.; Gloger, S.; Xie, L.; Jia, X.D.; Pejovic, V.; Miller, M.L.; Perhach, J.L.; Graham, S.M. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs, 2013, 27, 469-478.
56. Boinpally, R.; Chen, L.; Zukin, S.R.; McClure, N.; Hofbauer, R.K.; Periclou, A. A novel once-daily fixed-dose combination of memantine extended release and donepezil for the treatment of moderate to severe Alzheimer's disease: two phase i studies in healthy volunteers. Clin. Drug Investig., 2015, 35(7), 427-435.
57. Rosini, M.; Simoni, E.; Minarini, A.; Melchiorre, C. Multitarget design strategies in the context of Alzheimer's disease: acetylcholinesterase inhibition and NMDA receptor antagonism as the driving forces. Neurochem. Res., 2014, 39, 1914-1923.
58. Rosini, M.; Simoni, E.; Bartolini, M.; Cavalli, A.; Ceccarini, L.; Pascu, N.; McClymont, D.W.; Tarozzi, A.; Bolognesi, M.L.; Minarini, A.; Tumiatti, V.; Andrisano, V.; Mellor, I.R.; Melchiorre, C. Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multitarget- directed ligands gold rush. J. Med. Chem., 2008, 51, 4381-4384.
59. Lysko, P.G.; Lysko, K.A.; Webb, C.L.; Feuerstein, G.; Mason, P.E.; Walter, M.F.; Mason, R.P. Neuroprotective activities of carvedilol and a hydroxylated derivative: role of membrane biophysical interactions. Biochem. Pharmacol., 1998, 56, 1645-1656.
60. Howlett, D.R.; George, A.R.; Owen, D.E.; Ward, R.V.; Markwell, R.E. Common structural features determine the effectiveness of carvedilol, daunomycin and rolitetracycline as inhibitors of Alzheimer beta-amyloid fibril formation. Biochem. J., 1999, 343 (Pt 2), 419-423.
61. Simoni, E.; Daniele, S.; Bottegoni, G.; Pizzirani, D.; Trincavelli, M.L.; Goldoni, L.; Tarozzo, G.; Reggiani, A.; Martini, C.; Piomelli, D.; Melchiorre, C.; Rosini, M.; Cavalli, A. Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease. J. Med. Chem., 2012, 55, 9708-9721.
62. Busquet, P.; Capurro, V.; Cavalli, A.; Piomelli, D.; Reggiani, A.; Bertorelli, R. Synergistic effects of galantamine and memantine in attenuating scopolamine-induced amnesia in mice. J. Pharmacol. Sci., 2012, 120, 305-309.
63. Takada-Takatori, Y.; Kume, T.; Sugimoto, M.; Katsuki, H.; Sugimoto, H.; Akaike, A. Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology, 2006, 51, 474-486.
64. Bachurin, S.; Bukatina, E.; Lermontova, N.; Tkachenko, S.; Afanasiev, A.; Grigoriev, V.; Grigorieva, I.; Ivanov, Y.; Sablin, S.; Zefirov, N. Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann. N Y Acad. Sci., 2001, 939, 425-435.
65. Doody, R.S.; Gavrilova, S.I.; Sano, M.; Thomas, R.G.; Aisen, P.S.; Bachurin, S.O.; Seely, L.; Hung, D.; dimebon, I. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-tomoderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet, 2008, 372, 207-215.
66. Jones, R.W. Dimebon disappointment. Alzheimers Res. Ther., 2010, 2, 25.
67. Giorgetti, M.; Gibbons, J.A.; Bernales, S.; Alfaro, I.E.; Drieu La Rochelle, C.; Cremers, T.; Altar, C.A.; Wronski, R.; Hutter-Paier, B.; Protter, A.A. Cognition-enhancing properties of Dimebon in a rat novel object recognition task are unlikely to be associated with acetylcholinesterase inhibition or N-methyl-D-aspartate receptor antagonism. J. Pharmacol. Exp. Ther., 2010, 333, 748-757.
68. Rosini, M.; Simoni, E.; Bartolini, M.; Soriano, E.; Marco- Contelles, J.; Andrisano, V.; Monti, B.; Windisch, M.; Hutter- Paier, B.; McClymont, D.W.; Mellor, I.R.; Bolognesi, M.L. The bivalent ligand approach as a tool for improving the in vitro anti-Alzheimer multitarget profile of dimebon. Chem. Med. Chem., 2013, 8, 1276-1281.
69. Pang, Y.P.; Quiram, P.; Jelacic, T.; Hong, F.; Brimijoin, S. Highly potent, selective, and low cost bistetrahydroaminacrine inhibitors of acetylcholinesterase. Steps toward novel drugs for treating Alzheimer's disease. J. Biol. Chem., 1996, 271, 23646-23649.
70. Li, W.; Pi, R.; Chan, H.H.; Fu, H.; Lee, N.T.; Tsang, H.W.; Pu, Y.; Chang, D.C.; Li, C.; Luo, J.; Xiong, K.; Li, Z.; Xue, H.; Carlier, P.R.; Pang, Y.; Tsim, K.W.; Li, M.; Han, Y. Novel dimeric acetylcholinesterase inhibitor bis7-tacrine, but not donepezil, prevents glutamate-induced neuronal apoptosis by blocking N-methyl-D-aspartate receptors. J. Biol. Chem., 2005, 280, 18179-18188.
71. Rook, Y.; Schmidtke, K.U.; Gaube, F.; Schepmann, D.; Wunsch, B.; Heilmann, J.; Lehmann, J.; Winckler, T. Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J. Med. Chem., 2010, 53, 3611-3617.
72. Berlin, M.; Boyce, C.W.; Ruiz Mde, L. Histamine H3 receptor as a drug discovery target. J. Med. Chem., 2011, 54, 26-53.
73. Barbier, A.J.; Berridge, C.; Dugovic, C.; Laposky, A.D.; Wilson, S.J.; Boggs, J.; Aluisio, L.; Lord, B.; Mazur, C.; Pudiak, C.M.; Langlois, X.; Xiao, W.; Apodaca, R.; Carruthers, N.I.; Lovenberg, T.W. Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist. Br. J. Pharmacol., 2004, 143, 649-661.
74. Celanire, S.; Wijtmans, M.; Talaga, P.; Leurs, R.; de Esch, I.J. Keynote review: histamine H3 receptor antagonists reach out for the clinic. Drug Discov. Today, 2005, 10, 1613-1627.
75. Apelt, J.; Ligneau, X.; Pertz, H.H.; Arrang, J.M.; Ganellin, C.R.; Schwartz, J.C.; Schunack, W.; Stark, H. Development of a new class of nonimidazole histamine H(3) receptor ligands with combined inhibitory histamine Nmethyltransferase activity. J. Med. Chem., 2002, 45, 1128-1141.
76. Incerti, M.; Flammini, L.; Saccani, F.; Morini, G.; Comini, M.; Coruzzi, M.; Barocelli, E.; Ballabeni, V.; Bertoni, S. Dual-acting drugs: an in vitro study of nonimidazole histamine H3 receptor antagonists combining anticholinesterase activity. Chem. Med. Chem., 2010, 5, 1143-1149.
77. Keith, J.M.; Gomez, L.A.; Wolin, R.L.; Barbier, A.J.; Wilson, S.J.; Boggs, J.D.; Mazur, C.; Fraser, I.C.; Lord, B.; Aluisio, L.; Lovenberg, T.W.; Carruthers, N.I. Pyrrolidinotetrahydroisoquinolines as potent dual H3 antagonist and serotonin transporter inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 2603-2607.
78. Roche, O.; Rodriguez Sarmiento, R.M. A new class of histamine H3 receptor antagonists derived from ligand based design. Bioorg. Med. Chem. Lett., 2007, 17, 3670-3675.
79. Darras, F.H.; Kling, B.; Heilmann, J.; Decker, M. Neuroprotective tri- and tetracyclic BChE inhibitors releasing reversible inhibitors upon carbamate transfer. ACS Med. Chem. Lett., 2012, 3, 914-919.
80. Bembenek, S.D.; Keith, J.M.; Letavic, M.A.; Apodaca, R.; Barbier, A.J.; Dvorak, L.; Aluisio, L.; Miller, K.L.; Lovenberg, T.W.; Carruthers, N.I. Lead identification of acetylcholinesterase inhibitors-histamine H3 receptor antagonists from molecular modeling. Bioorg. Med. Chem., 2008, 16, 2968-2973.
81. Aliev, G.; Priyadarshini, M.; Reddy, V.P.; Grieg, N.H.; Kaminsky, Y.; Cacabelos, R.; Ashraf, G.M.; Jabir, N.R.; Kamal, M.A.; Nikolenko, V.N.; Zamyatnin, A.A., Jr.; Benberin, V.V.; Bachurin, S.O. Oxidative stress mediated mitochondrial and vascular lesions as markers in the pathogenesis of Alzheimer disease. Curr. Med. Chem., 2014, 21, 2208-2217.
82. Minarini, A.; Milelli, A.; Simoni, E.; Rosini, M.; Bolognesi, M.L.; Marchetti, C.; Tumiatti, V. Multifunctional tacrine derivatives in Alzheimer's disease. Curr. Top. Med. Chem., 2013, 13, 1771-1786.
83. Rodriguez-Franco, M.I.; Fernandez-Bachiller, M.I.; Perez, C.; Hernandez-Ledesma, B.; Bartolome, B. Novel tacrinemelatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties. J. Med. Chem., 2006, 49, 459-462.
84. Fernandez-Bachiller, M.I.; Perez, C.; Gonzalez-Munoz, G.C.; Conde, S.; Lopez, M.G.; Villarroya, M.; Garcia, A.G.; Rodriguez-Franco, M.I. Novel tacrine-8- hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimer's disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties. J. Med. Chem., 2010, 53, 4927-4937.
85. Fernandez-Bachiller, M.I.; Perez, C.; Monjas, L.; Rademann, J.; Rodriguez-Franco, M.I. New tacrine-4-oxo-4Hchromene hybrids as multifunctional agents for the treatment of Alzheimer's disease, with cholinergic, antioxidant, and beta-amyloid-reducing properties. J. Med. Chem., 2012, 55, 1303-1317.
86. Nepovimova, E.; Uliassi, E.; Korabecny, J.; Pena-Altamira, L.E.; Samez, S.; Pesaresi, A.; Garcia, G.E.; Bartolini, M.; Andrisano, V.; Bergamini, C.; Fato, R.; Lamba, D.; Roberti, M.; Kuca, K.; Monti, B.; Bolognesi, M.L. Multitarget drug design strategy: quinone-tacrine hybrids designed to block amyloid-beta aggregation and to exert anticholinesterase and antioxidant effects. J. Med. Chem., 2014, 57, 8576-8589.
87. Benchekroun, M.; Bartolini, M.; Egea, J.; Romero, A.; Soriano, E.; Pudlo, M.; Luzet, V.; Andrisano, V.; Jimeno, M.L.; Lopez, M.G.; Wehle, S.; Gharbi, T.; Refouvelet, B.; de Andres, L.; Herrera-Arozamena, C.; Monti, B.; Bolognesi, M.L.; Rodriguez-Franco, M.I.; Decker, M.; Marco- Contelles, J.; Ismaili, L. Novel tacrine-grafted Ugi adducts as multipotent anti-Alzheimer drugs: A synthetic renewal in tacrine-ferulic acid hybrids. Chem. Med. Chem., 2015, 10(3), 523-539.
88. Reiter, R.J.; Guerrero, J.M.; Garcia, J.J.; Acuna- Castroviejo, D. Reactive oxygen intermediates, molecular damage, and aging. Relation to melatonin. Ann. N Y Acad. Sci., 1998, 854, 410-424.
89. Fernandez-Bachiller, M.I.; Perez, C.; Campillo, N.E.; Paez, J.A.; Gonzalez-Munoz, G.C.; Usan, P.; Garcia-Palomero, E.; Lopez, M.G.; Villarroya, M.; Garcia, A.G.; Martinez, A.; Rodriguez-Franco, M.I. Tacrine-melatonin hybrids as multifunctional agents for Alzheimer's disease, with cholinergic, antioxidant, and neuroprotective properties. Chem. Med. Chem., 2009, 4, 828-841.
90. Huang, X.; Moir, R.D.; Tanzi, R.E.; Bush, A.I.; Rogers, J.T. Redox-active metals, oxidative stress, and Alzheimer's disease pathology. Ann. N Y Acad. Sci., 2004, 1012, 153-163.
91. Bareggi, S.R.; Cornelli, U. Clioquinol: review of its mechanisms of action and clinical uses in neurodegenerative disorders. CNS Neurosci. Ther., 2012, 18, 41-46.
92. Spencer, J.P. Beyond antioxidants: the cellular and molecular interactions of flavonoids and how these underpin their actions on the brain. Proc. Nutr. Soc., 2010, 69, 244-260.
93. Cavalli, A.; Bolognesi, M.L.; Capsoni, S.; Andrisano, V.; Bartolini, M.; Margotti, E.; Cattaneo, A.; Recanatini, M.; Melchiorre, C. A small molecule targeting the multifactorial nature of Alzheimer's disease. Angew Chem. Int. Ed. Engl., 2007, 46, 3689-3692.
94. Melchiorre, C.; Andrisano, V.; Bolognesi, M.L.; Budriesi, R.; Cavalli, A.; Cavrini, V.; Rosini, M.; Tumiatti, V.; Recanatini, M. Acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against Alzheimer's disease. J. Med. Chem., 1998, 41, 4186-4189.
95. Bolognesi, M.L.; Cavalli, A.; Melchiorre, C. Memoquin: a multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer's disease. Neurotherapeutics, 2009, 6, 152-162.
96. Bolognesi, M.L.; Cavalli, A.; Bergamini, C.; Fato, R.; Lenaz, G.; Rosini, M.; Bartolini, M.; Andrisano, V.; Melchiorre, C. Toward a rational design of multitarget-directed antioxidants: merging memoquin and lipoic acid molecular frameworks. J. Med. Chem., 2009, 52, 7883-7886.
97. Lopez-Iglesias, B.; Perez, C.; Morales-Garcia, J.A.; Alonso- Gil, S.; Perez-Castillo, A.; Romero, A.; Lopez, M.G.; Villarroya, M.; Conde, S.; Rodriguez-Franco, M.I. New melatonin- N,N-dibenzyl(N-methyl)amine hybrids: potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer's disease. J. Med. Chem., 2014, 57, 3773-3785.
98. Zhu, Y.; Xiao, K.; Ma, L.; Xiong, B.; Fu, Y.; Yu, H.; Wang, W.; Wang, X.; Hu, D.; Peng, H.; Li, J.; Gong, Q.; Chai, Q.; Tang, X.; Zhang, H.; Shen, J. Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and beta-secretase. Bioorg. Med. Chem., 2009, 17, 1600-1613.
99. Piazzi, L.; Cavalli, A.; Colizzi, F.; Belluti, F.; Bartolini, M.; Mancini, F.; Recanatini, M.; Andrisano, V.; Rampa, A. Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds. Bioorg. Med. Chem. Lett., 2008, 18, 423-426.
100. Bolognesi, M.L.; Chiriano, G.; Bartolini, M.; Mancini, F.; Bottegoni, G.; Maestri, V.; Czvitkovich, S.; Windisch, M.; Cavalli, A.; Minarini, A.; Rosini, M.; Tumiatti, V.; Andrisano, V.; Melchiorre, C. Synthesis of monomeric derivatives to probe memoquin's bivalent interactions. J. Med. Chem., 2011, 54, 8299-8304.
101. Hernandez-Rodriguez, M.; Correa-Basurto, J.; Martinez- Ramos, F.; Padilla, M., II; Benitez-Cardoza, C.G.; Mera- Jimenez, E.; Rosales-Hernandez, M.C. Design of multitarget compounds as AChE, BACE1, and amyloid-beta(1- 42) oligomerization inhibitors: in silico and in vitro studies. J. Alzheimers Dis., 2014, 41, 1073-1085.
102. Lu, S.H.; Wu, J.W.; Liu, H.L.; Zhao, J.H.; Liu, K.T.; Chuang, C.K.; Lin, H.Y.; Tsai, W.B.; Ho, Y. The discovery of potential acetylcholinesterase inhibitors: a combination of pharmacophore modeling, virtual screening, and molecular docking studies. J. Biomed. Sci., 2011, 18, 8.
103. John, S.; Thangapandian, S.; Sakkiah, S.; Lee, K.W. Potent BACE-1 inhibitor design using pharmacophore modeling, in silico screening and molecular docking studies. BMC Bioinformatics, 2011, 12(Suppl 1), S28.
104. Viayna, E.; Gomez, T.; Galdeano, C.; Ramirez, L.; Ratia, M.; Badia, A.; Clos, M.V.; Verdaguer, E.; Junyent, F.; Camins, A.; Pallas, M.; Bartolini, M.; Mancini, F.; Andrisano, V.; Arce, M.P.; Rodriguez-Franco, M.I.; Bidon- Chanal, A.; Luque, F.J.; Camps, P.; Munoz-Torrero, D. Novel huprine derivatives with inhibitory activity toward beta-amyloid aggregation and formation as diseasemodifying anti-Alzheimer drug candidates. Chem. Med. Chem., 2010, 5, 1855-1870.
105. Viayna, E.; Sola, I.; Bartolini, M.; De Simone, A.; Tapia- Rojas, C.; Serrano, F.G.; Sabate, R.; Juarez-Jimenez, J.; Perez, B.; Luque, F.J.; Andrisano, V.; Clos, M.V.; Inestrosa, N.C.; Munoz-Torrero, D. Synthesis and multitarget biological profiling of a novel family of rhein derivatives as disease-modifying anti-Alzheimer agents. J. Med. Chem., 2014, 57, 2549-2567.
106. Dominguez, J.L.; Fernandez-Nieto, F.; Castro, M.; Catto, M.; Paleo, M.R.; Porto, S.; Sardina, F.J.; Brea, J.M.; Carotti, A.; Villaverde, M.C.; Sussman, F. Computer-aided structure-based design of multitarget leads for Alzheimer's disease. J. Chem. Inf. Model., 2014, 55, 135-148.
107. Weinreb, O.; Amit, T.; Bar-Am, O.; Youdim, M.B. A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor. Int. Rev. Neurobiol., 2011, 100, 191-215.
108. Weinreb, O.; Amit, T.; Bar-Am, O.; Youdim, M.B. Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr. Drug Targets, 2012, 13, 483-494.
109. Bolea, I.; Juarez-Jimenez, J.; de Los Rios, C.; Chioua, M.; Pouplana, R.; Luque, F.J.; Unzeta, M.; Marco-Contelles, J.; Samadi, A. Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1Hindol- 2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease. J. Med. Chem., 2011, 54, 8251-8270.
110. Bautista-Aguilera, O.M.; Esteban, G.; Bolea, I.; Nikolic, K.; Agbaba, D.; Moraleda, I.; Iriepa, I.; Samadi, A.; Soriano, E.; Unzeta, M.; Marco-Contelles, J. Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil-indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease. Eur. J. Med. Chem., 2014, 75, 82-95.
111. Bautista-Aguilera, O.M.; Samadi, A.; Chioua, M.; Nikolic, K.; Filipic, S.; Agbaba, D.; Soriano, E.; de Andres, L.; Rodriguez- Franco, M.I.; Alcaro, S.; Ramsay, R.R.; Ortuso, F.; Yanez, M.; Marco-Contelles, J. N-Methyl-N-((1-methyl-5- (3-(1-(2-methylbenzyl)piperidin-4-yl)propoxy)-1H-indol-2- yl)methyl)prop-2-yn-1-amine, a New Cholinesterase and Monoamine Oxidase Dual Inhibitor. J. Med. Chem., 2014, 57, 10455-10463.
112. Samadi, A.; de los Rios, C.; Bolea, I.; Chioua, M.; Iriepa, I.; Moraleda, I.; Bartolini, M.; Andrisano, V.; Galvez, E.; Valderas, C.; Unzeta, M.; Marco-Contelles, J. Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine. Eur. J. Med. Chem., 2012, 52, 251-262.
113. Robert, S.; Maillet, M.; Morel, E.; Launay, J.M.; Fischmeister, R.; Mercken, L.; Lezoualc'h, F. Regulation of the amyloid precursor protein ectodomain shedding by the 5-HT4 receptor and Epac. FEBS Lett., 2005, 579, 1136-1142.
114. Cho, S.; Hu, Y. Activation of 5-HT4 receptors inhibits secretion of beta-amyloid peptides and increases neuronal survival. Exp. Neurol., 2007, 203, 274-278.
115. Lezoualc'h, F. 5-HT4 receptor and Alzheimer's disease: the amyloid connection. Exp. Neurol., 2007, 205, 325-329.
116. Freret, T.; Bouet, V.; Quiedeville, A.; Nee, G.; Dallemagne, P.; Rochais, C.; Boulouard, M. Synergistic effect of acetylcholinesterase inhibition (donepezil) and 5-HT(4) receptor activation (RS67333) on object recognition in mice. Behav. Brain Res., 2012, 230, 304-308.
117. Lecoutey, C.; Hedou, D.; Freret, T.; Giannoni, P.; Gaven, F.; Since, M.; Bouet, V.; Ballandonne, C.; Corvaisier, S.; Malzert Freon, A.; Mignani, S.; Cresteil, T.; Boulouard, M.; Claeysen, S.; Rochais, C.; Dallemagne, P. Design of donecopride, a dual serotonin subtype 4 receptor agonist/ acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment. Proc. Natl. Acad. Sci. USA, 2014, 111, E3825-E3830.
118. Rochais, C.; Lecoutey, C.; Gaven, F.; Giannoni, P.; Hamidouche, K.; Hedou, D.; Dubost, E.; Genest, D.; Yahiaoui, S.; Freret, T.; Bouet, V.; Dauphin, F.; Sopkova de Oliveira Santos, J.; Ballandonne, C.; Corvaisier, S.; Malzert-Freon, A.; Legay, R.; Boulouard, M.; Claeysen, S.; Dallemagne, P. Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer's disease: the design of donecopride. J. Med. Chem., 2015, 58, 3172-3187.
119. Huang, W.; Lv, D.; Yu, H.; Sheng, R.; Kim, S.C.; Wu, P.; Luo, K.; Li, J.; Hu, Y. Dual-target-directed 1,3- diphenylurea derivatives: BACE 1 inhibitor and metal chelator against Alzheimer's disease. Bioorg. Med. Chem., 2010, 18, 5610-5615.
120. Mufson, E.J.; Counts, S.E.; Perez, S.E.; Ginsberg, S.D. Cholinergic system during the progression of Alzheimer's disease: therapeutic implications. Expert. Rev. Neurother., 2008, 8, 1703-1718.
121. Terry, A.V., Jr.; Buccafusco, J.J. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J. Pharmacol. Exp. Ther., 2003, 306, 821-827.
122. Gonzalez-Naranjo, P.; Campillo, N.E.; Perez, C.; Paez, J.A. Multitarget cannabinoids as novel strategy for Alzheimer disease. Curr. Alzheimer Res., 2013, 10, 229-239.
123. Maroof, N.; Pardon, M.C.; Kendall, D.A. Endocannabinoid signalling in Alzheimer's disease. Biochem. Soc. Trans., 2013, 41, 1583-1587.
124. Aso, E.; Ferrer, I. Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic. Front. Pharmacol., 2014, 5, 37.
125. Páez, J.A., Campillo, N.E., González-Naranjo, P.; Pérez, C., Arán, V.J. Martín-Fontelles, M.I., Girón R., Sánchez, E.M. Preparation of 3-Indazolyl Ethers with Cannabinoid and/or Cholinergic Properties Useful for Treating Various Diseases. PCT/ES2010-000400) 2009.
126. Gonzalez-Naranjo, P.; Perez-Macias, N.; Campillo, N.E.; Perez, C.; Aran, V.J.; Giron, R.; Sanchez-Robles, E.; Martin, M.I.; Gomez-Canas, M.; Garcia-Arencibia, M.; Fernandez- Ruiz, J.; Paez, J.A. Cannabinoid agonists showing Bu- ChE inhibition as potential therapeutic agents for Alzheimer's disease. Eur. J. Med. Chem., 2014, 73, 56-72.
127. Preece, P.; Virley, D.J.; Costandi, M.; Coombes, R.; Moss, S.J.; Mudge, A.W.; Jazin, E.; Cairns, N.J. Beta-secretase (BACE) and GSK-3 mRNA levels in Alzheimer's disease. Brain Res. Mol. Brain Res., 2003, 116, 155-158.
128. Stamford, A.; Strickland, C. Inhibitors of BACE for treating Alzheimer's disease: a fragment-based drug discovery story. Curr. Opin. Chem. Biol., 2013, 17, 320-328.
129. Martinez, A.; Perez, D.I.; Gil, C. Lessons learnt from glycogen synthase kinase 3 inhibitors development for Alzheimer's disease. Curr. Top. Med. Chem., 2013, 13, 1808-1819.
130. Prati, F.; De Simone, A.; Bisignano, P.; Armirotti, A.; Summa, M.; Pizzirani, D.; Scarpelli, R.; Perez, D.I.; Andrisano, V.; Perez-Castillo, A.; Monti, B.; Massenzio, F.; Polito, L.; Racchi, M.; Favia, A.D.; Bottegoni, G.; Martinez, A.; Bolognesi, M.L.; Cavalli, A. multitarget drug discovery for Alzheimer's disease: triazinones as BACE-1 and GSK-3beta inhibitors. Angew. Chem. Int. Ed. Engl., 2015, 54, 1578-1582.
131. Korcsmaros, T.; Szalay, M.S.; Bode, C.; Kovacs, I.A.; Csermely, P. How to design multi-target drugs. Expert. Opin. Drug Discov., 2007, 2, 799-808.
132. Leon, R.; Marco-Contelles, J. A step further towards multitarget drugs for Alzheimer and neuronal vascular diseases: targeting the cholinergic system, amyloid-beta aggregation and Ca(2+) dyshomeostasis. Curr. Med. Chem., 2011, 18, 552-576.
133. Speck-Planche, A.; Kleandrova, V.V.; Luan, F.; Cordeiro, M.N. Multi-target inhibitors for proteins associated with Alzheimer: in silico discovery using fragment-based descriptors. Curr. Alzheimer Res., 2013, 10, 117-124.
134. Hieke, M.; Ness, J.; Steri, R.; Dittrich, M.; Greiner, C.; Werz, O.; Baumann, K.; Schubert-Zsilavecz, M.; Weggen, S.; Zettl, H. Design, synthesis, and biological evaluation of a novel class of gamma-secretase modulators with PPARgamma activity. J Med. Chem., 2010, 53, 4691-4700.